(BEAM) Beam Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 2.789m USD | Total Return: 68.2% in 12m
Avg Turnover: 57.0M
Qual. Beats: 0
Rev. Trend: -26.1%
Qual. Beats: 0
Warnings
Share dilution 17.4% YoY
High Debt/EBITDA (12.9) with thin interest coverage (-1.9)
High Debt while negative Cash Flow
Interest Coverage Ratio -1.9 is critical
Altman Z'' -4.69 < 1.0 - financial distress zone
Choppy Below Avwap Earnings
Tailwinds
No distinct edge detected
Beam Therapeutics Inc. is a biotechnology company headquartered in Cambridge, Massachusetts, focused on developing precision genetic medicines through base editing technology. The company’s pipeline targets serious conditions including sickle cell disease, alpha-1 antitrypsin deficiency, and glycogen storage disease type 1a. Its business model relies on a combination of internal drug development and strategic research collaborations with established pharmaceutical entities such as Pfizer.
The company utilizes a proprietary base editing platform designed to enable precise, single-base changes in the genome without inducing double-strand DNA breaks. This approach represents a specific niche within the broader gene-editing sector, which seeks to provide permanent therapeutic solutions for monogenic diseases. Beam’s technical infrastructure includes the ESCAPE platform for stem cell conditioning and lipid nanoparticle (LNP) delivery systems for liver-targeted therapies.
Investors can further evaluate these technical milestones and clinical trial timelines by reviewing the detailed data available on ValueRay. The firm maintains active partnerships with Verve Therapeutics and Orbital Therapeutics to expand its reach into cardiovascular and RNA-based treatments.
- Clinical trial data readouts for sickle cell therapy BEAM-101 drive valuation volatility
- Regulatory approval timeline for liver-targeting lipid nanoparticle platform determines long-term revenue potential
- Strategic collaboration milestones with Pfizer provide essential non-dilutive capital and validation
- High research and development expenditures necessitate frequent secondary equity offerings to sustain operations
| Net Income: -65.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.04 > 0.02 and ΔFCF/TA 12.50 > 1.0 |
| NWC/Revenue: 727.0% < 20% (prev 1.74k%; Δ -1.01k% < -1%) |
| CFO/TA -0.25 > 3% & CFO -369.7m > Net Income -65.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 16.99 > 1.5 & < 3 |
| Outstanding Shares: last quarter (103.3m) vs 12m ago 17.38% < -2% |
| Gross Margin: -35.84% > 18% (prev -3.72%; Δ -3.21k% > 0.5%) |
| Asset Turnover: 11.13% > 50% (prev 4.33%; Δ 6.79% > 0%) |
| Interest Coverage Ratio: -1.95 > 6 (EBITDA TTM -62.8m / Interest Expense TTM 43.7m) |
| A: 0.81 (Total Current Assets 1.27b - Total Current Liabilities 74.6m) / Total Assets 1.48b |
| B: -1.17 (Retained Earnings -1.74b / Total Assets 1.48b) |
| C: -0.06 (EBIT TTM -85.2m / Avg Total Assets 1.47b) |
| D: -5.49 (Book Value of Equity -1.74b / Total Liabilities 316.4m) |
| Altman-Z'' = -4.69 = D |
As of May 26, 2026, the stock is trading at USD 28.64 with a total of 1,327,200 shares traded.
Over the past week, the price has changed by +2.54%,
over one month by -1.80%,
over three months by -3.28% and
over the past year by +68.17%.
Beam Therapeutics has received a consensus analysts rating of 4.41. Therefore, it is recommended to buy BEAM.
- StrongBuy: 10
- Buy: 4
- Hold: 3
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.1 | 78.3% |
P/S = 17.0053
P/B = 2.3263
Revenue TTM = 164.0m USD
EBIT TTM = -85.2m USD
EBITDA TTM = -62.8m USD
Long Term Debt = 100.2m USD (from longTermDebt, last quarter)
Short Term Debt = 14.8m USD (from shortTermDebt, last quarter)
Debt = 401.5m USD (from shortLongTermDebtTotal, last quarter) + Leases 150.6m
Net Debt = -810.2m USD (calculated: Debt 401.5m - CCE 1.21b)
Enterprise Value = 1.98b USD (2.79b + Debt 401.5m - CCE 1.21b)
Interest Coverage Ratio = -1.95 (Ebit TTM -85.2m / Interest Expense TTM 43.7m)
EV/FCF = -30.72x (Enterprise Value 1.98b / FCF TTM -64.4m)
FCF Yield = -3.26% (FCF TTM -64.4m / Enterprise Value 1.98b)
FCF Margin = -39.28% (FCF TTM -64.4m / Revenue TTM 164.0m)
Net Margin = -39.66% (Net Income TTM -65.0m / Revenue TTM 164.0m)
Gross Margin = -35.84% ((Revenue TTM 164.0m - Cost of Revenue TTM 222.8m) / Revenue TTM)
Gross Margin QoQ = 82.34% (prev none%)
Tobins Q-Ratio = 1.34 (Enterprise Value 1.98b / Total Assets 1.48b)
Interest Expense / Debt = 10.89% (Interest Expense 43.7m / Debt 401.5m)
Taxrate = 21.0% (US default 21%)
NOPAT = -67.3m (EBIT -85.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.59 (Total Current Assets 1.27b / Total Current Liabilities 86.9m)
Debt / Equity = 0.34 (Debt 401.5m / totalStockholderEquity, last quarter 1.16b)
Debt / EBITDA = 12.90 (negative EBITDA) (Net Debt -810.2m / EBITDA -62.8m)
Debt / FCF = 12.58 (negative FCF - burning cash) (Net Debt -810.2m / FCF TTM -64.4m)
Total Stockholder Equity = 1.10b (last 4 quarters mean from totalStockholderEquity)
RoA = -4.41% (Net Income -65.0m / Total Assets 1.48b)
RoE = -2.29% (Net Income TTM -65.0m / Total Stockholder Equity 2.84b)
RoCE = -2.90% (EBIT -85.2m / Capital Employed (Equity 2.84b + L.T.Debt 100.2m))
RoIC = -5.18% (negative operating profit) (NOPAT -67.3m / Invested Capital 1.30b)
WACC = 13.18% (E(2.79b)/V(3.19b) * Re(13.84%) + D(401.5m)/V(3.19b) * Rd(10.89%) * (1-Tc(0.21)))
Discount Rate = 13.84% (= CAPM, Blume Beta Adj.) -> capped to 13.17%
Shares (quarterly) Correlation: 82.22 | Cagr: 10.37%
[DCF] Fair Price = unknown (Cash Flow -64.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.21 | # QB: 0
Revenue Correlation: -26.05 | Revenue CAGR: -20.57% | SUE: 0.53 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.15 | Chg30d=-9.59% | Revisions=-43% | Analysts=12
EPS next Quarter (2026-09-30): EPS=-1.20 | Chg30d=-10.30% | Revisions=-43% | Analysts=12
EPS current Year (2026-12-31): EPS=-4.51 | Chg30d=-4.44% | Revisions=+12% | GrowthEPS=-456.3% | GrowthRev=-47.6%
EPS next Year (2027-12-31): EPS=-4.82 | Chg30d=-9.75% | Revisions=-7% | GrowthEPS=-6.9% | GrowthRev=+25.8%
[Analyst] Revisions Ratio: -43%